Evotec Stock - weekly review after a muted trading spell
19.06.2026 - 13:57:08 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 13:56 CET. Details in the imprint.
Evotec (DE0005664809) has delivered a quiet week in the absence of new official announcements. With no fresh ad-hoc or major analyst changes emerging on Friday, the focus turns to where the biotech stock stands in a weekly review against its sector peers.
All news and data on Evotec stock
Find historical reports, background and price data on Evotec to put the current trading week into context.
What this trading week shows
Evotec shares have traded in a relatively narrow range this week on Xetra, with the quote around mid-week at roughly EUR 4.60 according to exchange data. Price data from finanzen.ch The move has been muted compared with earlier high-volatility phases.
Over the past months, the stock had reacted strongly to restructuring news and management updates, but no comparable triggers surfaced in the last few days. Against this backdrop, trading activity appears more driven by sector sentiment than by company-specific headlines.
How Evotec compares with peers
Within the European biotech universe, Evotec’s market capitalization in the mid-hundreds of millions of euros positions the company below large-cap drug developers but above many early-stage peers. Market overview on MarketScreener The stock therefore often trades as a mid-cap collaboration specialist rather than a pure-play biotech start-up.
Weekly sector sentiment has been shaped more by global risk appetite and interest-rate expectations than by individual pipeline milestones. For investors tracking benchmarks, Evotec typically sits in the broader European healthcare and biotech cohort, where risk-sensitive names have seen alternating support and pressure this year.
How the company makes money
Evotec’s business model centers on research alliances and development partnerships for new medicines, spanning drug discovery, preclinical research and selected clinical programs. The company earns revenues from research payments, milestones and potential royalties on successful partnered products.
Where the stock trades today
The shares of Evotec (DE0005664809) trade on Xetra at EUR 4.54 as of 06/19/2026, 13:30 CET.
Key facts on Evotec stock
- Company: Evotec SE
- ISIN: DE0005664809
- WKN: 566480
- Ticker: EVT
- Venue: Xetra
- Price (as of 06/19/2026, 13:30 CET): 4.54 EUR
- Market cap: approximately 807,000,000 EUR (as of 06/19/2026)
- Sector / Industry: Healthcare / Biotechnology
- Index membership: TecDAX
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
